{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T11:37:25Z","timestamp":1768822645000,"version":"3.49.0"},"reference-count":39,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CEOR"],"DOI":"10.2147\/ceor.s559251","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T12:20:15Z","timestamp":1768220415000},"page":"1-16","source":"Crossref","is-referenced-by-count":0,"title":["Economic Evaluation of Ready-to-Dilute Thiotepa (Tepylute\u00ae): Institutional Cost Offsets and Time Savings Compared to Lyophilized Thiotepa in a United States Hospital Pharmacy"],"prefix":"10.2147","volume":"Volume 18","author":[{"given":"Orlaith","family":"Ryan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurice","family":"Clancy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alanna","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Pastor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Bourque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,1]]},"reference":[{"key":"ref1","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox: clinical and research information on drug-induced liver injury: alkylating agents. Bethesda (MD). Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547849\/. Accessed June 12, 2025."},{"key":"ref2","unstructured":"US Centers for Disease Control and Prevention. NIOSH list of hazardous drugs in healthcare setting, 2024. 2024. Available from: https:\/\/www.cdc.gov\/niosh\/docs\/2025-103\/pdfs\/2025-103.pdf?id=10.26616\/NIOSHPUB2025103. Accessed February 27, 2025."},{"key":"ref3","unstructured":"ADIENNE pharma and biotech. In: thiotepa, editor. Zurigo, Switzerland. 2017."},{"key":"ref4","unstructured":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. THIOTEPA. Pharmaceuticals. Lyon (FR): International Agency for Research on Cancer; 2012. (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, No. 100A)."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/cncr.29023","volume":"121","author":"Chen","year":"2015","journal-title":"Cancer"},{"key":"ref6","first-page":"1642","volume":"127","author":"Ferreri","year":"2016","journal-title":"Blood J Am Soc Hematol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e388","DOI":"10.1016\/S2352-3026(16)30050-3","volume":"3","author":"Illerhaus","year":"2016","journal-title":"Lancet Haematol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1080\/13696998.2018.1467918","volume":"21","author":"Hess","year":"2018","journal-title":"J Med Econ"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/jcpt.12529","volume":"42","author":"Terkola","year":"2017","journal-title":"J Clin Pharm Therapeutics"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1177\/10781552221146529","volume":"29","author":"Chaudhari","year":"2023","journal-title":"J Oncol Pharm Pract"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1136\/amiajnl-2011-000332","volume":"19","author":"Rodriguez-Gonzalez","year":"2012","journal-title":"J Am Med Inf Assoc"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/cncr.31950","volume":"125","author":"Reinhardt","year":"2019","journal-title":"Cancer"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"6788","DOI":"10.3390\/ijerph20186788","volume":"20","author":"Castro","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"ejhpharm\u20132024","DOI":"10.1136\/ejhpharm-2024-004444","author":"Gallina","year":"2025","journal-title":"Eur J Hosp Pharm"},{"key":"ref15","unstructured":"National Toxicology Program. Thiotepa 15th report on carcinogens. No. 52-24-4. ed. Research triangle park (NC). 2021."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.procs.2023.01.431","volume":"219","author":"Gon\u00e7alves","year":"2023","journal-title":"Procedia Comput Sci"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3322\/canjclin.56.6.354","volume":"56","author":"Connor","year":"2006","journal-title":"Ca a Cancer J Clinicians"},{"key":"ref18","unstructured":"Shorla Oncology. SH-105 A treatment for breast & ovarian cancer. Available from: https:\/\/shorlaoncology.com\/pipeline\/sh-105\/. Accessed October 3, 2024."},{"key":"ref19","unstructured":"Shorla Oncology. In: TEPYLUTE (thiotepa), editor. Cambridge, MA. 2025."},{"key":"ref20","unstructured":"HOPA. Intravenous cancer drug waste issue brief. 2022. Available from: https:\/\/www.hoparx.org\/documents\/65\/HOPA_Drug_Waste_Issue_Brief_-_Updated_01.19.22_FINAL.pdf. Accessed February 21, 2025."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"3976","DOI":"10.1016\/j.vaccine.2015.06.030","volume":"33","author":"De Coster","year":"2015","journal-title":"Vaccine"},{"key":"ref22","unstructured":"Business Wire. Eagle pharmaceuticals announces TREAKISYM (bendamustine) ready-to-dilute (\u201cRTD\u201d) formulation, in combination with rituximab for treatment of relapsed or refractory diffuse large B-cell lymphoma receives PMDA approval in Japan. 2021. Available from: https:\/\/www.businesswire.com\/news\/home\/20210430005136\/en. Accessed December 19, 2025."},{"key":"ref23","unstructured":"Medicine E, National Academies of Sciences. Medications in Single-Dose Vials: Implications of Discarded Drugs. 2021."},{"key":"ref24","unstructured":"Symphony Integrated Dataverse. Administrative open claims data from symphony integrated dataverse, Jan 2022-Dec 2023 Accessed October 2023."},{"key":"ref25","unstructured":"NAVLIN by EVERSANA. NAVLIN price & access data tool. Available from: https:\/\/www.eversana.com\/ko\/products\/pricentric-one\/. Accessed November 29, 2023."},{"key":"ref26","unstructured":"EVERSANA Custom Insights. Final report: opportunities and barriers for SH105. 2024."},{"key":"ref27","unstructured":"Eversana open claims database. Jan 2022-Dec 2023 Accessed October, 2023."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1007\/s10072-015-2259-1","volume":"36","author":"Chahal","year":"2015","journal-title":"Neurol Sci"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1177\/548.6510","volume":"96","author":"Cozzi","year":"2010","journal-title":"Tumori J"},{"key":"ref30","unstructured":"IQVIA - SMART US Edition. Data reflective of utilization for 12 months ending May 2024. Accessed June 2024."},{"key":"ref31","unstructured":"Occupational employment and wages, May 2023 (2023)."},{"key":"ref32","unstructured":"Machlin SR, Mitchell EM. Expenses for office-based physician visits by specialty and insurance type, 2016. 2018."},{"key":"ref33","unstructured":"Liang L, Moore B, Soni A. National inpatient hospital costs: the most expensive conditions by payer, 2017. 2020."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1177\/10781552231170358","volume":"30","author":"Boyd","year":"2024","journal-title":"J Oncol Pharm Pract"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2147\/CEOR.S297284","volume":"Volume 13","author":"James","year":"2021","journal-title":"Clinicoecon Outcomes Res"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s40122-022-00402-z","volume":"11","author":"Arora","year":"2022","journal-title":"Pain Ther"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s00228-019-02631-2","volume":"75","author":"Larmen\u00e9-Beld","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"ref38","first-page":"10600280231212890","author":"Benhamou","year":"2023","journal-title":"Ann Pharmacother"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s10916-023-01953-0","volume":"47","author":"Tu","year":"2023","journal-title":"J Med Systems"}],"container-title":["ClinicoEconomics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/article\/download\/110922","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/article\/download\/110922","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T12:20:32Z","timestamp":1768220432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/economic-evaluation-of-ready-to-dilute-thiotepa-tepylute-institutional-peer-reviewed-fulltext-article-CEOR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":39,"URL":"https:\/\/doi.org\/10.2147\/ceor.s559251","relation":{},"ISSN":["1178-6981"],"issn-type":[{"value":"1178-6981","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}